 |
|
Effects of a 'Drug Holiday' on Bone Mineral Density and Bone Turnover Marker During Bisphosphonate Therapy
Sung Yeol Kong, Dae Young Kim, Eun Jin Han, So Young Park, Chang Hoon Yim, Sung Hoon Kim, Hyun Koo Yoon
J Bone Metab. 2013;20(1):31-35. Published online 2013 May 13 DOI: https://doi.org/10.11005/jbm.2013.20.1.31
|
|
Citations to this article as recorded by
 Real-world bone turnover marker use: impact on treatment decisions and fracture
N. E. Lane, K. Saag, T. J. O’Neill, M. Manion, R. Shah, U. Klause, R. Eastell
Osteoporosis International.2021; 32(5): 831. CrossRef Pharmacology of bisphosphonates
Serge Cremers, Matthew T. Drake, F. Hal Ebetino, John P. Bilezikian, R. Graham G. Russell
British Journal of Clinical Pharmacology.2019; 85(6): 1052. CrossRef Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy
Vivek Thumbigere-Math, Bryan S. Michalowicz, Pamela J. Hughes, David L. Basi, Michaela L. Tsai, Karen K. Swenson, Laura Rockwell, Rajaram Gopalakrishnan
Journal of Oral and Maxillofacial Surgery.2016; 74(4): 738. CrossRef Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday
L. H. R. Xu, B. Adams-Huet, J. R. Poindexter, N. M. Maalouf
Osteoporosis International.2016; 27(5): 1701. CrossRef Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study
Gi Hyeon Seo, Hyung Jin Choi
Journal of Bone Metabolism.2015; 22(2): 77. CrossRef Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans
J. LaFleur, S.L. DuVall, T. Willson, T. Ginter, O. Patterson, Y. Cheng, K. Knippenberg, C. Haroldsen, R.A. Adler, J.R. Curtis, I. Agodoa, R.E. Nelson
Bone.2015; 78: 174. CrossRef
|